Posts Tagged ‘CagriSema’

ADA2023 in San Diego: Watching Tides Roll In

June 24, 2023 — Suddenly at the ADA2023 meeting in San Diego, it seems the tides are rolling in to promise more options than ever before for treating obesity. By tides we mean all those drugs targeting the GLP-1 receptors. GLP-1 is shorthand for glucagon-like peptide 1. Most, but not all of these drugs making a splash in San […]

A New Combination Therapy Hits the Mark

August 26, 2022 — Progress keeps coming in the pharmacotherapy for obesity. This week, Novo Nordisk announced that its new combination therapy of semaglutide and cagrilintide hit all its marks in a 32-week phase 2 study of patients with diabetes and excess weight. The combination – Novo is calling it CagriSema – worked better than either semaglutide or cagrilintide […]